Display options
Cite
Boutari C, Polyzos SA, Mantzoros CS. Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism. 2021;122:154781doi: 10.1016/j.metabol.2021.154781.
Boutari, C., Polyzos, S. A., & Mantzoros, C. S. (2021). Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism: clinical and experimental, 122154781. https://doi.org/10.1016/j.metabol.2021.154781
Boutari, Chrysoula, et al. "Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward." Metabolism: clinical and experimental vol. 122 (2021): 154781. doi: https://doi.org/10.1016/j.metabol.2021.154781
Boutari C, Polyzos SA, Mantzoros CS. Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism. 2021 Sep;122:154781. doi: 10.1016/j.metabol.2021.154781. Epub 2021 Apr 24. PMID: 33901501.
Copy Download .nbib Format: NLM
Share it on

Metabolism. 2021 Sep;122:154781. doi: 10.1016/j.metabol.2021.154781. Epub 2021 Apr 24.

Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward.

Metabolism: clinical and experimental

Chrysoula Boutari, Stergios A Polyzos, Christos S Mantzoros

Affiliations

  1. Second Propedeutic Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
  2. First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  3. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Medicine, Boston VA Healthcare System, Boston, MA, USA. Electronic address: [email protected].

PMID: 33901501 DOI: 10.1016/j.metabol.2021.154781

[No abstract available.]

Keywords: Clinical care pathway; Diabetes; Guidelines; Multidisciplinary approach; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity; Stakeholders

Conflict of interest statement

Declaration of competing interest CB and SAP have no competing interests. CSM has been a shareholder of and reports grants through his institution and personal consulting fees from Coherus and AltrixB

MeSH terms

Publication Types